Innovimmune Biotherapeutics

Executive Summary

Innovimmune Biotherapeutics is a privately-held preclinical biotechnology company developing novel oral small molecule immunomodulators for cancer and autoimmune diseases. Founded in 2017 and headquartered in New York, the company focuses on first-in-class and best-in-class New Chemical Entities (NCEs) targeting immune pathways. While still in the exploratory development stage, Innovimmune's approach aims to address significant unmet needs in oncology and autoimmune disorders by leveraging oral administration for improved patient convenience and compliance. The company operates in a competitive landscape but benefits from a focused pipeline and proprietary technology. Given its early stage, Innovimmune faces typical preclinical risks including candidate selection, toxicity, and efficacy in animal models. However, its novel mechanism and oral modality could differentiate it if successful. The company has not disclosed funding rounds or partnerships, suggesting it may be self-funded or in early discussions. Overall, Innovimmune represents a high-risk, high-reward opportunity pending advancement of its lead candidates into IND-enabling studies.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate selection for IND-enabling studies60% success
• Q3 2026Completion of preclinical efficacy data in autoimmune disease models70% success
• Q2 2027Potential Series A financing or strategic partnership40% success